ASCO 2017 Prostate Cancer - Results from #60

Viewing 61-80 of 85 articles

ASCO 2017: Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer from the phase 3 Prevail clinical trial

ASCO 2017: BRCA1/2 reversion mutations in prostate cancer identified from clinical tissue and liquid biopsy samples

ASCO 2017: Next-generation sequencing of tissue and cell free DNA (cfDNA) to identify somatic and germline alterations in advanced prostate cancer

ASCO 2017: A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209

ASCO 2017: The benefit of combining docetaxel to androgen deprivation therapy in localized and metastatic castration-sensitive prostate cancer as predicted by ERG status: An analysis of two GETUG phase III trials

ASCO 2017: Need for re-evaluation of current guidelines based on results from germline genetic testing in prostate cancer

ASCO 2017: Liquid Biopsies: Current Utility and Future Directions

ASCO 2017: Selection, Timing, and Interpretation of Metastatic Castration-Resistant Prostate Cancer Lesions

ASCO 2017: Challenges in Translating Molecular Results Into Meaningful Clinical Use

ASCO 2017: Results of LATITUDE: ADT with Abiraterone Acetate Plus Prednisone in High-Risk Metastatic Hormone-Naive Prostate Cancer

ASCO 2017: Genomic Selection for Prostate Cancer: Are We Ready?

ASCO 2017: Interpreting Biomarkers and Trial Outcomes: How Confident Are We?

ASCO 2017: Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial

ASCO 2017: Circulating tumor cell number as a response endpoint in metastatic castration resistant compared with PSA across five randomized phase 3 trials

ASCO 2017: Phase 3 prognostic analysis of the automated bone scan index in men with bone-metastatic castration-resistant prostate cancer

ASCO 2017: Making Androgen Receptor Targeted Therapy Great Again

ASCO 2017: Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone vs enzalutamide in men with AR-V7+ metastatic castration-resistant prostate cancer

ASCO 2017: A phase IV, randomized, double-blind, placebo-controlled study of continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naive mCRPC

ASCO 2017: Adding abiraterone for men with high-risk prostate cancer starting long-term androgen deprivation therapy: Survival results from STAMPEDE

ASCO 2017: Abiraterone + prednisone +/- veliparib for patients with metastatic castration-resistant prostate cancer: Updated clinical and genomics data

1
2
3
4
5